Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

Launched by HANSA BIOPHARMA AB · Jan 27, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term health of kidney transplant patients who have a high level of antibodies that can make it difficult to find a matching donor. The study is specifically focused on patients who previously participated in another trial, called ConfIdeS, where they received a treatment called imlifidase to help prepare them for a kidney transplant. Researchers want to learn how well these patients do over time, including their survival rates and how well their new kidneys are functioning.

To be eligible for this trial, participants must have already signed consent for the earlier study and must not have any reasons that would prevent them from joining, as decided by the study team. If you qualify, you can expect to be part of a study that aims to improve the chances of successful kidney transplants for people with high antibody levels. Your involvement will help doctors understand the best ways to support patients in similar situations in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed Informed Consent obtained before any trial-related procedures.
• • 2. Previous participation in the clinical trial ConfIdeS.
• Exclusion Criteria:
• • 1. Inability by the judgement of the investigator to participate in the trial for any reason.